New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 5, 2013
16:35 EDTACT, SOMXSomaxon announces settlement of Silenor patent litigation with Actavis
Somaxon Pharmaceuticals (SOMX) announced that it has entered into a settlement agreement with Actavis Elizabeth and Actavis (ACT) to resolve pending patent litigation involving Silenor 3 mg and 6 mg tablets. The settlement agreement grants Actavis the right to begin selling a generic version of Silenor on January 1, 2020, or earlier under certain circumstances. The settlement agreement will become effective upon the entry by the U.S. District Court for the District of Delaware of an order dismissing the litigation with respect to Actavis.
News For SOMX;ACT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for SOMX;ACT

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use